YAP1-fusions in pediatric NF2-wildtype meningioma

2019/11/16 by Philipp Sievers, Jason Chiang, Daniel Schrimpf +27 · 28 citations
Biochemistry, Genetics and Molecular Biology · Medicine · #Hippo pathway signaling and YAP/TAZ #Neurofibromatosis and Schwannoma Cases #Meningioma and schwannoma management

paper · doi:10.1007/s00401-019-02095-9

Cited by

• YAP1::MAML2 fusion-positive high-grade neuroepithelial tumors with rhabdoid morphology and inflammatory microenvironment: Implications for integrated diagnosis
• Accurate calling of KIAA1549‐BRAF fusions from DNA of human brain tumours using methylation array‐based copy number and gene panel sequencing data
• The Hippo pathway in cancer: YAP/TAZ and TEAD as therapeutic targets in cancer
• Comparison of tumor-associated YAP1 fusions identifies a recurrent set of functions critical for oncogenesis. [europepmc]
• Intracranial mesenchymal tumor with FET-CREB fusion-A unifying diagnosis for the spectrum of intracranial myxoid mesenchymal tumors and angiomatoid fibrous histiocytoma-like neoplasms. [europepmc]
• Clear cell meningiomas are defined by a highly distinct DNA methylation profile and mutations in SMARCE1. [europepmc]
• YAP1 and its fusion proteins in cancer initiation, progression and therapeutic resistance. [europepmc]
• Leveraging the replication-competent avian-like sarcoma virus/tumor virus receptor-A system for modeling human gliomas. [europepmc]
• TAZ-CAMTA1 and YAP-TFE3 alter the TAZ/YAP transcriptome by recruiting the ATAC histone acetyltransferase complex. [europepmc]
• Mutations and Copy Number Abnormalities of Hippo Pathway Components in Human Cancers. [europepmc]
• EANO guideline on the diagnosis and management of meningiomas. [europepmc]
• YAP1-MAML2 Fusion as a Diagnostic Biomarker for Metaplastic Thymoma. [europepmc]
• Molecular profiling of pediatric meningiomas shows tumor characteristics distinct from adult meningiomas. [europepmc]
• The Hippo pathway in cancer: YAP/TAZ and TEAD as therapeutic targets in cancer. [europepmc]
• The oncogenic fusion landscape in pediatric CNS neoplasms. [europepmc]
• Meningioma DNA methylation groups identify biological drivers and therapeutic vulnerabilities. [europepmc]
• A single-cell based precision medicine approach using glioblastoma patient-specific models. [europepmc]
• YAP1-MAML2 fusion in a pediatric NF2-wildtype intraparenchymal brainstem schwannoma. [europepmc]
• Both YAP1-MAML2 and constitutively active YAP1 drive the formation of tumors that resemble NF2 mutant meningiomas in mice. [europepmc]
• TAZ/YAP fusion proteins: mechanistic insights and therapeutic opportunities. [europepmc]
• Pediatric meningioma with a Novel MAML2-YAP1 fusion variant: a case report and literature review. [europepmc]
• Atypical Intraparenchymal Meningioma with YAP1-MAML2 Fusion in a Young Adult Male: A Case Report and Mini Literature Review. [europepmc]
• Meningioma animal models: a systematic review and meta-analysis. [europepmc]
• Unveiling a Biomarker Signature of Meningioma: The Need for a Panel of Genomic, Epigenetic, Proteomic, and RNA Biomarkers to Advance Diagnosis and Prognosis. [europepmc]
• Meningioma: current updates on genetics, classification, and mouse modeling. [europepmc]
• Meningioma transcriptomic landscape demonstrates novel subtypes with regional associated biology and patient outcome. [europepmc]
• Aggressive high-grade NF2 mutant meningiomas downregulate oncogenic YAP signaling via the upregulation of VGLL4 and FAT3/4. [europepmc]
• YAP, TAZ, and Hippo-Dysregulating Fusion Proteins in Cancer. [europepmc]